The positive effects of the HPV ( Human Papilloma Virus ) vaccine have been highlighted again in a study by researchers at Kings College, published this Wednesday in ‘The Lancet’.The study has followed up on the immunization program against the human papillomavirus (HPV), confirming that cervical cancer is up to 87% lower in transient women.
In this sense, the HPV vaccine, free in Spain since 2008, has as one of its main objectives to prevent the development of cancer.To date, the studies carried out had shown positive results among those vaccinated, something that is confirmed by this new analysis by the British researchers.
The viruses are so widespread that vaccination should be directed at minors before they become sexually active. It should be remembered that the HPV vaccine can only prevent infection , it cannot eliminate the virus from the body once it has been contracted.
It should be remembered that there are more than 100 types of human papillomavirus. The UK started using a vaccine that protects against two of them and is about to introduce a new one that protects against nine viruses , including the main ones that cause genital warts.Five – year survival ranges from 90% to 40% depending on the stage of the disease.
DEVELOPMENT OF THE STUDY
The research, funded by the Center for Cancer Research, UK , analyzed registry data from January 2006 to June 2019 with women who had been screened for cervical cancer between the ages of 20 and 64. years, including those women who received the Cervarix vaccine after it became available in 2008.
During the nearly 13-year period, there were approximately 28,000 diagnoses of cervical cancer and 300,000 diagnoses of a precancerous condition calledCervical intraepithelial neoplasia (CIN3) data collected in England.
They concluded that, as of June 2019, there were around 450 fewer cases of cervical cancer and 17,200 fewer cases of cervical carcinomas (pre-cancers) than expected in the vaccinated population in England. The most pronounced decrease with respect to unvaccinated women occurs in those who were injected between 12 and 13 years of age (87%), but the drop in incidence persists in adolescents who were vaccinated at an older age.
The cancer rate was 62% lower when the vaccines were given between the ages of 14 and 16 and was reduced by 34% in women vaccinated between the ages of16 and 18 years according to a study published in the journal ”The Lancet”.
On the other hand, the rates of a possibleprecancerous condition were also reduced by 97%, in the cases in which the vaccines were administered at 12 and 13 years. The authors of the study state with satisfaction: “The results obtained should reassure those who still have doubts about the benefits of vaccination against HPV.”
“We trust that these new results will encourage vaccination , since the success of the program depends not only on the efficacy of the vaccine, but also on the proportion of the population vaccinated “,, from the UK Health Security Agency.
